L-Glutamine ： Irritable Bowel Syndrome (IBS)
CPilot RCTs suggest glutamine (5 g TID) reduces intestinal permeability and IBS-D symptoms in post-infectious IBS. Promising but needs larger trials.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dl\u002Dglutamine\u0026condition\u003Dibs';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
結論
Pilot RCTs suggest glutamine (5 g TID) reduces intestinal permeability and IBS-D symptoms in post-infectious IBS. Promising but needs larger trials.
Key Study Findings
Other
Unraveling the active ingredients and molecular mechanisms of Qinghua Changyan granule against irritable bowel syndrome …
Dose: None
vs: None
Outcome: IBS-D symptom relief via gut microbiota and glutamine …
効果: None
None
対象集団: animal model of IBS with diarrhea
Other
n=25
4 weeks
Effect of probiotic administration of Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917 …
Dose: Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917
vs: phosphate-buffered saline (PBS)
Outcome: visceral hypersensitivity (abdominal withdrawal reflex scores)
効果: None
p<0.05
対象集団: female rats with water avoidance stress-induced IBS-D model
Other
n=62
[Study on activation mechanism of SGCs in representation along the distribution of stomach meridian in …
Dose: None
vs: Control group (no citrobacter)
Outcome: SGC activation in DRG segments
効果: None
P<0.05 to P<0.01
対象集団: Male C57BL/6 mice (IBS-D model)
Review
Intestinal Barrier Impairment, Preservation, and Repair: An Update.
Dose: None
vs: None
Outcome: Intestinal barrier preservation and repair
効果: None
None
対象集団: IBD and IBS patients (review)
Other
Multi-Omics Reveals the Effects of Cannabidiol on Gut Microbiota and Metabolic Phenotypes.
Dose: None
vs: None
Outcome: Cholesterol levels
効果: None
None
対象集団: Mouse model
In Vitro
Effects of Glutamine, Curcumin and Fish Bioactive Peptides Alone or in Combination on Intestinal Permeability …
Dose: None
vs: None
Outcome: inflammation markers
効果: None
None
対象集団: Mice
Key Statistics
2
研究数
150
参加者数
↑
Positive
C
グレード
Referenced Papers
Fitoterapia
2026
1 件の引用
Journal of the …
2026
Zhongguo zhen jiu …
2025
Nutrients
2024
47 件の引用
Cannabis and cannabinoid …
2024
10 件の引用
International journal of …
2023
9 件の引用
Journal of gastroenterology
2022
23 件の引用
NeuroImage. Clinical
2022
8 件の引用
Digestion
2021
29 件の引用
Frontiers in nutrition
2021
17 件の引用
Medicine
2021
Nutrition research (New …
2020
42 件の引用
World journal of …
2020
11 件の引用
Gut
2019
148 件の引用
Metabolomics : Official …
2019
41 件の引用
Pain
2019
23 件の引用
Scientific reports
2019
14 件の引用
Gut
2019
5 件の引用
[Not Available].
RCT
Praxis
2018
Current opinion in …
2017
71 件の引用
JPEN. Journal of …
2016
44 件の引用
Gastroenterology
2015
17 件の引用
Frontline gastroenterology
2012
20 件の引用
The American journal …
2011
48 件の引用
Clinical nutrition (Edinburgh, …
2011
12 件の引用
MicroRNA-29a regulates intestinal membrane permeability in patients with irritable bowel syndrome.
Other
Gut
2010
263 件の引用
Clinics (Sao Paulo, …
2010
47 件の引用
Zhong xi yi …
2009
6 件の引用
Journal of clinical …
2008
73 件の引用
Nutrition in clinical …
2008
42 件の引用
Journal of proteome …
2006
80 件の引用
Medycyna wieku rozwojowego
2004
1 件の引用
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
一般的な使用量
- general:
- 5-15 g/day
- ibsdsupport:
- 5 g three times daily (15 g/day total)
- postexercisegut:
- 0.25-0.9 g/kg before intense exercise
- gutbarriersupport:
- 0.5 g/kg/day (approximately 30-40 g/day for adults)
上限量： Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day
研究で検討された用量
| 用量 | 期間 | 効果 | N |
|---|---|---|---|
| None | -- | Positive | -- |
| Bifidobacterium animalis subsp. lactis BB-12 and Lactiplantibacillus plantarum ATCC 14917 | 4 weeks | Positive | 25 |
| None | -- | Mixed | 62 |
| None | -- | Positive | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Negative | 75 |
推奨摂取タイミング： Between meals or before exercise; divide doses throughout the day
Safety & Side Effects
報告されている副作用
- ⚠ Mild gastrointestinal discomfort at high doses
- ⚠ Headache
- ⚠ Dizziness at very high doses
- ⚠ Potential glutamate excitotoxicity concerns in neurological conditions (theoretical)
既知の相互作用
- ● Lactulose (glutamine may reduce the efficacy of lactulose for hepatic encephalopathy)
- ● Anti-seizure medications (glutamine converts to glutamate; theoretical concern)
- ● Chemotherapy agents (glutamine may protect cancer cells; discuss with oncologist)
耐容上限摂取量： Generally well-tolerated up to 0.5 g/kg/day; caution above 40 g/day
サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
Frequently Asked Questions
Does L-Glutamine help with Irritable Bowel Syndrome (IBS)?
Based on 2 studies with 150 participants, there is limited but promising evidence that L-Glutamine may support Irritable Bowel Syndrome (IBS) management. Our evidence grade is C (Some Evidence).
How much L-Glutamine should I take for Irritable Bowel Syndrome (IBS)?
Studies have used various dosages. A commonly studied range is 5-15 g/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of L-Glutamine?
Reported side effects may include Mild gastrointestinal discomfort at high doses, Headache, Dizziness at very high doses, Potential glutamate excitotoxicity concerns in neurological conditions (theoretical). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for L-Glutamine and Irritable Bowel Syndrome (IBS)?
We rate the evidence as Grade C (Some Evidence). This rating is based on 2 peer-reviewed studies with 150 total participants. The overall direction of effect is positive.
Related Evidence
に関する他の成分： Irritable Bowel Syndrome (IBS)
L-Glutamine 他の症状・状態について
FDAに関する免責事項: これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。